Free Online Event: Explore Safer, Non-Surgical Alternatives for Chronic Pain Relief Chalfont & Quakertown, PA – September 29, 2025, at 7:00 PM ET
-- Feeling isolated and misunderstood by chronic nerve pain? The Pennsylvania Pain & Spine Institute invites community members to a free, live virtual webinar revealing a cutting-edge, non-invasive therapy that’s already transforming pain management outcomes for local Pennsylvania patients.
The program will be led by top pain specialists Dr. Robert Kelly, Dr. Jeffrey Boyd, and Dr. David Bozak, who will explain how the therapy works, review its potential benefits, and discuss whether it may be appropriate for certain patients based on their medical history and ongoing needs.
Unlike surgical procedures or long-term prescription plans, this new treatment option provides a non-invasive approach that may reduce pain and improve quality of life. The webinar will provide participants with straightforward, evidence-based information to help them understand the therapy and make informed decisions about their care.
What Attendees Will Learn:
- An overview of the therapy and how it works
- Which patients may benefit most from this chronic pain treatment
- How it differs from traditional surgical or medication-based treatments
- Answers to patient questions in a live Q&A session with pain specialists
Event Details:
- Date: Monday, September 29, 2025
- Time: 7:00 PM ET
- Duration: Approximately 1 hour
- Format: Online webinar – registration required
Local Access to Care for Pennsylvania Residents
The Pennsylvania Pain & Spine Institute provides this therapy and other advanced pain management services at its offices in Chalfont (1500 Horizon Drive, Suite #102B) and Quakertown (401 W. Broad St, Suite #1), making these treatment options accessible to patients throughout Bucks, Lehigh, and Montgomery Counties in Pennsylvania.
How to Attend & Take Control of Chronic Pain—Penn Pain Webinar
Highlights Non-Surgical Treatment Options
This event is free to attend, but space is limited. To reserve a place in the webinar, please register online here.
FDA-Approved Chronic Neuropathic Pain Relief Therapy
This new pain relief therapy, Saluda’s Evoke Spinal Cord Stimulation (SCS) System, is FDA-approved to treat chronic neuropathic pain of the trunk and/or limbs. This includes conditions such as failed back surgery syndrome and intractable low back and leg pain.
At the discretion of the treating physician, spinal cord stimulation may also be considered for other types of nerve-related pain, including:
- Sciatica
- Neuropathy (diabetic, chemotherapy-induced, or peripheral)
- Complex Regional Pain Syndrome (CRPS/RSD)
- Postherpetic neuralgia (shingles-related pain)
- Occipital neuralgia (head and neck nerve pain)
- Radiculopathy (nerve pain radiating into arms or legs)
The Evoke System uses advanced real-time feedback technology to continuously monitor and adjust stimulation, helping provide consistent pain relief tailored to each patient’s needs. This non-invasive therapy is designed to reduce pain, improve quality of life, and offer an alternative to surgery or long-term medication use.
To learn more about this pain relief option and see if it’s a fit, sign up to attend the webinar or make an appointment at Pennsylvania Pain & Spine Institute.
Contact Info:
Name: Melissa Silber
Email: Send Email
Organization: Pennsylvania Pain & Spine Institute
Phone: 609-923-5563
Website: https://bit.ly/4683TKo
Release ID: 89170297
Should you detect any errors, issues, or discrepancies with the content contained within this press release, or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond and take necessary steps within the next 8 hours to resolve any identified issues or guide you through the removal process. We value the trust placed in us by our readers and remain dedicated to providing accurate and reliable information.
